AbCellera Biologics Inc. announced that the United States Court of Appeals for the Federal Circuit has confirmed the validity of its U.S. Patent No. 10,087,408 related to microfluidic devices used for culturing and selectively recovering cells. The Federal Circuit upheld this decision by a Rule 36 Order, following a challenge by Bruker Cellular Analysis, Inc., which claimed the patent was invalid due to anticipation and obviousness over prior art. This patent is central to an ongoing multi-patent infringement litigation with Bruker. AbCellera expressed satisfaction with the ruling, emphasizing its commitment to defending its intellectual property.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250512115715) on May 12, 2025, and is solely responsible for the information contained therein.